Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioCryst Pharmaceuticals Inc

BCRX
Current price
4.43 USD -0.07 USD (-1.56%)
Last closed 4.5 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 966 843 520 USD
Yield for 12 month -39.97 %
1Y
3Y
5Y
10Y
15Y
BCRX
21.11.2021 - 28.11.2021

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.82 USD

P/E ratio

Dividend Yield

Current Year

+331 412 000 USD

Last Year

+270 827 000 USD

Current Quarter

+93 401 000 USD

Last Quarter

+86 742 000 USD

Current Year

+325 096 000 USD

Last Year

+264 233 000 USD

Current Quarter

+91 341 000 USD

Last Quarter

+85 606 000 USD

Key Figures BCRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -95 914 000 USD
Operating Margin TTM -40.41 %
PE Ratio
Return On Assets TTM -11.57 %
PEG Ratio -0.28
Return On Equity TTM -1925.37 %
Wall Street Target Price 13.82 USD
Revenue TTM 331 412 000 USD
Book Value -2.21 USD
Revenue Per Share TTM 1.72 USD
Dividend Share
Quarterly Revenue Growth YOY 17.4 %
Dividend Yield
Gross Profit TTM 10 936 000 USD
Earnings Share -1.18 USD
Diluted Eps TTM -1.18 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -68.36 %

Dividend Analytics BCRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BCRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BCRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4.2832
Price Sales TTM 2.9671
Enterprise Value EBITDA -12.2018
Price Book MRQ 56.5858

Financials BCRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BCRX

For 52 weeks

4.45 USD 9.07 USD
50 Day MA 5.28 USD
Shares Short Prior Month 30 546 519
200 Day MA 6.15 USD
Short Ratio 9.45
Shares Short 32 252 059
Short Percent 17.4 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics